Psoriatic Arthritis at Risk for Interstitial Lung Disease A TriNetX EHR study shows that psoriatic arthritis (PsA), but

Tweet Author

Tweet Content

Psoriatic Arthritis at Risk for Interstitial Lung Disease A TriNetX EHR study shows that psoriatic arthritis (PsA), but not Psoriasis (PsO), patients are at increased risk for interstitial lung disease (ILD). https://t.co/2zuxF1PY3Q. https://t.co/r28dY3T8nO

Links

Psoriatic Arthritis at Risk for Interstitial Lung Disease | RheumNow https://buff.ly/hXhemE3

Extract of purple sweet potato ANTHOCYANINS (PSPA) studied in CIA animal model of #RA; Rats Rx w PBO or PSPA (10, 20, or

Tweet Author

RheumNow

Tweet Content

Extract of purple sweet potato ANTHOCYANINS (PSPA) studied in CIA animal model of #RA; Rats Rx w PBO or PSPA (10, 20, or 40 mg/kg) x14days. 40mg/kg dose reduced synovitis, altered gut microbiota (Akkermansia, Lactobacillus) decr RF & cytokines TNF-α, IL-1β, IL-6, IL-18) https://t.co/UjPFEuTU1S

9 June 2025

Secukinumab Use in Refractory Giant Cell Arteritis

In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger phase 3 trial, there is a 6 patient case series also suggesting the efficacy of IL-17 inhibition in GCA, not responding to TCZ.

A case series of six GCA patients from three centres in Italy. All were treated with secukinumab (300 mg SC weekly for four weeks, then 300 mg monthly). Clinical outcomes were assessed at six months.

Uncontrolled pilot trial of frequency specific microcurrent treatment given to 17 pts w/ Raynaud’s & systemic scl

Tweet Author

RheumNow

Tweet Content

Uncontrolled pilot trial of frequency specific microcurrent treatment given to 17 pts w/ Raynaud’s & systemic sclerosis. Microcurrent Rx given for 45-60 min over 1-2d; w/ average improvement of 40% in hand function & Raynauds improvement ~18% p .016)- RCT needed!! https://t.co/4OUeODuj8Q

9 June 2025

2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia

A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA patients may be instrumental in preventing RA.

A EULAR and ACR expert committee was established.

Swiss Registry study of PsA outcomes when started on either TNFi (N 503) or IL-17i (n 341), latter w/ more severe PSO.

Tweet Author

RheumNow

Tweet Content

Swiss Registry study of PsA outcomes when started on either TNFi (N 503) or IL-17i (n 341), latter w/ more severe PSO. IL-17i durability superior to TNFi (median 828 vs 445 d, P<.001), w/ less D/C in women (HR 0.57); but ACR 20 (14 v 33%) & ACR50 (7 v 24%) favored TNFi use https://t.co/R33bwSeB3E

52 wk Phase 3 DBRPCT of daily anakinra (100 mg sc) vs PBO in 30 giant cell arteritis pts. At wk 16 (17 ANK vs 13 PBO)

Tweet Author

RheumNow

Tweet Content

52 wk Phase 3 DBRPCT of daily anakinra (100 mg sc) vs PBO in 30 giant cell arteritis pts. At wk 16 (17 ANK vs 13 PBO) there was no significant difference in relapse rates (12% vs 23%; p = 0.63). Same at wk 52 (53% vs 49% relapse). ANK didnt reduce relapses or GC exposure https://t.co/RFkkaUchsW

Global incidence of alopecia areata increased betw 1990 - 2021; from 20.43 million (19.77-21.09 million) in 1990 to 30.8

Tweet Author

RheumNow

Tweet Content

Global incidence of alopecia areata increased betw 1990 - 2021; from 20.43 million (19.77-21.09 million) in 1990 to 30.89 million in 2021 ( range of 29.95-31.82 million) - highest in USA 550/100,000. High in N.America, S.America, Southeast Asia, Australia. Lowestin Africa, Middle https://t.co/GxrZPY5NBc

Review of Emerging Treatments for Vitiligo an immune mediated dz that affects QOL & has psychosocial impact. JAKi o

Tweet Author

RheumNow

Tweet Content

Review of Emerging Treatments for Vitiligo an immune mediated dz that affects QOL & has psychosocial impact. JAKi only ruxolitinib is FDA-approved, but Tofa & Bari show promise. Emerging therapies include simvastatin, afamelanotide, and metformin https://t.co/Rp2yYx6SyZ https://t.co/3RbDFVtJR5

Links

Future of Vitiligo Treatment: Emerging Therapies, Impact on Quality of Life https://buff.ly/o1KU3AH

CMAJ reminds us that w/ parvovirus B19 infection, Arthropathy seen in ~60% of adolescents & adults, but the classic

Tweet Author

RheumNow

Tweet Content

CMAJ reminds us that w/ parvovirus B19 infection, Arthropathy seen in ~60% of adolescents & adults, but the classic “slapped cheek rash” is uncommon. Symmetric, polyarticular inflamm arthralgias/itis affects PIPs, MCPS mostly. Sxs resolve w/in 3 wks. ~20% can last mos-yrs https://t.co/WXnuViSLbe

Topics

Psoriatic Arthritis at Risk for Interstitial Lung Disease A TriNetX EHR study shows that psoriatic arthritis (PsA), but

Extract of purple sweet potato ANTHOCYANINS (PSPA) studied in CIA animal model of #RA; Rats Rx w PBO or PSPA (10, 20, or

Uncontrolled pilot trial of frequency specific microcurrent treatment given to 17 pts w/ Raynaud’s & systemic scl

Swiss Registry study of PsA outcomes when started on either TNFi (N 503) or IL-17i (n 341), latter w/ more severe PSO.

52 wk Phase 3 DBRPCT of daily anakinra (100 mg sc) vs PBO in 30 giant cell arteritis pts. At wk 16 (17 ANK vs 13 PBO)

Global incidence of alopecia areata increased betw 1990 - 2021; from 20.43 million (19.77-21.09 million) in 1990 to 30.8

Review of Emerging Treatments for Vitiligo an immune mediated dz that affects QOL & has psychosocial impact. JAKi o

CMAJ reminds us that w/ parvovirus B19 infection, Arthropathy seen in ~60% of adolescents & adults, but the classic

Do you get our email newsletter?